| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 19DG7G1U5Q |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C21H16FN7 |
| Molecular Weight | 385.41 |
| AlogP | 4.28 |
| Hydrogen Bond Acceptor | 6.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 4.0 |
| Polar Surface Area | 92.27 |
| Molecular species | None |
| Aromatic Rings | 5.0 |
| Heavy Atoms | 29.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | PI3-kinase p110-delta subunit inhibitor |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Transferase
|
- | 10.9-18 | - | - | -2.219-6.31 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | -12.88-17.66 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Carcinoma, Squamous Cell | 2 | D002294 | ClinicalTrials |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | D015451 | ClinicalTrials |
| Lymphoma, Large B-Cell, Diffuse | 1 | D016403 | ClinicalTrials |
| Lymphoma, Mantle-Cell | 1 | D020522 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL3545048 |
| FDA SRS | 19DG7G1U5Q |
| PubChem | 68947304 |
CONTENTS